Candida vulvovaginitis overview

Candida vulvovaginitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Candidiasis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

Other Imagining Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Candida vulvovaginitis overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Candida vulvovaginitis overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Candida vulvovaginitis overview

CDC on Candida vulvovaginitis overview

Candida vulvovaginitis overview in the news

Blogs on Candida vulvovaginitis overview

Directions to Hospitals Treating Candidiasis

Risk calculators and risk factors for Candida vulvovaginitis overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

## Overview

[edit | edit source]

Candida vulvovagintis is an infection of the vagina and the vestibulum, common in women in the reproductive age group. It is caused by various Candida species with Candida albicans most common pathogen followed by other species like Candida glabarta, Candida krusei etc. Patients present with vulvar pruritus, burning micturition and vaginal discharge.The diagnosis of candidal infection requires a collaboration of clinical and diagnostic findings. Patients have typical white cottage chesee like discharge with hyphae and spores demonstrated on microscopy. Patients with uncomplicated infection respond well to topical and oral azole therapy. 5 to 8% of women develop recurrent vaginitis, which is defined as more than 4 episodes in a year. These patients require a longer duration of therapy with an induction and maintenance phase.

## Historical Perspective

[edit | edit source]

In 1839, B. Lagenbeck from Germany described a yeast-like fungus for the first time in the human oral infection thrush and its ability to cause it.

## Classification

[edit | edit source]

Candida vulvovaginitis can be classified based on the duration, as well as the strain of Candida causing the infection.

## Pathophysiology

[edit | edit source]

Several virulence factors of Candida are implicated in vulvovaginitis, but the process of transition from asymptomatic vaginal colonization to symptomatic vulvovaginitis is poorly understood. There may be genetic factors associated with Candida vulvovaginitis, as infection runs in families in many cases and is more common in African-American women.

## Causes

[edit | edit source]

Candida yeasts are usually present in most people, but uncontrolled multiplication resulting in disease symptoms is kept in check by other naturally occurring microorganisms, e.g., bacteria co-existing with the yeasts in the same locations, and by the human immune system.

In a study of 1009 women in New Zealand, the fungus, Candida albicans, was isolated from the vaginas of 19% of apparently healthy women. Carriers experienced few or no symptoms. However, external use of irritants (such as some detergents or douches) or internal disturbances (hormonal or physiological) can perturb the normal flora, constituting lactic acid bacteria, such as lactobacilli, and an overgrowth of yeast can result in noticeable symptoms. Pregnancy, the use of oral contraceptives, engaging in vaginal sex immediately and without cleansing after anal sex, and using lubricants containing glycerin have been found to be causally related to yeast infections. Diabetes mellitus and the use of antibiotics are also linked to an increased incidence of yeast infections. Candidiasis can be sexually transmitted from men to women, but not from a woman to a man. Diet has been found to be the cause in some animals. Hormone Replacement Therapy and infertility treatments may also be predisposing factors.

## Differentiating candida vulvovaginitis from other Diseases

[edit | edit source]

Candida Vulvovaginitis must be differentiated from diseases with similar presentation such as bacterial vaginosis, trichomonas vaginitis and atrophic vaginitis.

## Epidemiology and Demographics

[edit | edit source]

Candida vulvovaginitis is not a reportable disease and epidemiological studies on the prevalence of the disease are hard to perform.

## Risk Factors

[edit | edit source]

Antibiotics used to treat other types of infections change the normal balance between organisms in the vagina by decreasing the number of protective bacteria. Being pregnant, having diabetes, or being obese all create conditions that help yeast grow more easily.

## Screening

[edit | edit source]

There are no screening recommendations for candida vulvovaginitis.

## Natural History, Complications and Prognosis

[edit | edit source]

Candida vulvovaginitis is a self limiting disease with no complications, but few patients develop recurrence. Candida vulvovaginitis is very responsive to local or oral antifungals.

## Diagnosis

[edit | edit source]

### History and Symptoms

[edit | edit source]

Pruritus is the most significant symptom and candida infection is characterized by a thick, white "cottage cheese-like" vaginal discharge

### Physical Examination

[edit | edit source]

Physical examination of of the genitalia will demonstrate edema and erythema of the vulva and labia with fissures and excoriations of the external genitalia.Thick whitish vaginal discharge adherent to the vaginal walls may be present.

### Laboratory Findings

[edit | edit source]

A small amount of the vaginal discharge is examined using a microscope (called a wet mount and KOH test). Sometimes, a culture is taken when the infection does not improve with treatment or recurs many times.

## Treatment

[edit | edit source]

### Medical Therapy

[edit | edit source]

Antifungal agents are indicated in candidiasis. Commonly used drugs include Amphotericin, Clotrimazole, Nystatin, Fluconazole and Ketoconazole.

### Surgery

[edit | edit source]

There is no role for surgery in the treatment of Candida vulvovaginitis. Medical therapy with topical and/or oral anti-fungal drugs is the mainstay of treatment.

## Prevention

[edit | edit source]

### Primary Prevention

[edit | edit source]

There are no means to prevent Candida vulvovaginitis, but wearing a cotton underwear may help reduce the risk of infection.

### Secondary Prevention

[edit | edit source]

Prevention of recurrent vulvovaginal candidiasis, maintenance fluconazole prophylaxis may be used.[1] Treatment of a male sexual partner with oral ketoconazole does not seem to influence the cure or recurrence rates in women with Candida vulvovaginitis.

## References

[edit | edit source]

Template:WS